NCT07773948|Not Yet RecruitingPhase 4
ASAPP Study - Topical 5-ASA as Prophylaxis for Pouchitis in Ulcerative Colitis Patients After Pelvic Pouch Surgery
ASAPP
Loading search results
ASAPP
Sponsor study identifier
interventional
110
1 country
1
Study Start
April 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
March 31, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
March 31, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Ulcerative colitis (UC) is a chronic intestinal disease, often debuting early in life, and affecting the colon and rectum. The therapy is mainly medical and based on 5-aminosalicylic acid (5-ASA) and steroids. The last 20 years numerous new advanced therapies have become available and introduced more and more early after diagnosis. Surgery is still needed in refractory disease and will cure most patients, while ending up with a stoma. There is conflicting data on whether advanced therapies are decreasing the need for surgery or not. Reconstruction of bowel continuity is usually possible but somehow performed in less than 50% of Swedish patients. Restorative proctectomy with ileal pouch (created of the last part of the small bowel) anal anastomosis (IPAA) is gold standard. As of this year it is centralized to 4 units in Sweden. One complication after IPAA is pouchitis, an inflammation in the pouch that behaves like UC. More than half of all patients will have at least one flare of pouchitis, and some will develop chronic or recurrent pouchitis. Recent publications have shown an increased risk of pouchitis after the introduction of advanced therapies, but the reasons for this are still unknown. Prophylactic therapy with 5-ASA after IPAA surgery have been suggested. All patients in Sweden going through IPAA surgery due to UC will be invited to be part of this randomized controlled study to evaluate if 5-ASA can diminish the risk of pouchitis in UC.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 31, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 11, 2026
Actual (reported)August 19, 2026
Actual (reported)April 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
March 31, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
March 31, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Any event of pouchitis at two years follow up defined as a Pouchitis Disease Activity Index (PDAI) of ≥7.
Pouchitis Disease Activity Index runs from 0-18, where 0 is no symptoms and 18 worst possible symptoms. In case of pouchitis the severity will be graded according to Endoscopic Pouch Score (EPS). 1. Compare time to first event of pouchitis between 5-ASA and placebo prophylaxis. 2. Number of patients having had pouchitis at 3 months, 6 months, 1 and 2 years from having afunctioning pelvic pouch (closure of stoma if diverted at time of pouch creation). 3. Compare response rates of antibiotics and advanced therapy, respectively, in patients developing pouchitis after 5-ASA prophylaxis and placebo. 4. Assess patient satisfaction, health related quality of life (HRQoL), and bowel function and in relation to treatment strategy using questionnaires (Short Health Scale, SF36, Öresland score). 5. Assessment of mucosal permeability (by using an Ussing chamber)
Within two years of functioning restorative proctocolectomy
5-ASA suppositories
Placebo suppositories
Topical prophylactic treatment of pouchitis after restorative proctocolectomy
Topical placebor after restorative påroctocolectomy
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Linköping University Hospital
Linköping, 58185, Sweden
First Submitted
August 11, 2026
First Posted
August 19, 2026
Study Start
April 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
Adalimumab in the Treatment of Chronic Pouchitis
Contact the study team to confirm eligibility.
March 31, 2031
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
March 31, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
August 19, 2026
Record last verified: 2026-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: